On January 4, 2022 Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies for RAS-addicted cancers, reported that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will deliver a corporate presentation as part of the 40th Annual J.P. Morgan Healthcare Conference (Press release, Revolution Medicines, JAN 4, 2022, View Source [SID1234598025]). The conference, which will take place January 10-13, 2022, will be conducted in a virtual format.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As a centerpiece of the update, Dr. Goldsmith will announce the expansion of the company’s development-stage pipeline of RAS(ON) Inhibitors. Additionally, he will outline ongoing development plans for the company’s first two RAS(ON) Inhibitor programs: RMC-6236 (RASMULTI) and RMC-6291 (KRASG12C), and provide updates on its two clinical-stage RAS Companion Inhibitors: RMC-4630 (SHP2 inhibitor) and RMC-5552 (mTORC1/4EBP1 inhibitor).

Details of the company’s participation are as follows:

40th Annual J.P. Morgan Healthcare Conference
Conference Dates: January 10-13, 2022
Presentation Timing: 2:15 p.m. Eastern on Tuesday, January 11, 2022
Format: Virtual conference; webcast available
To access the live webcast of the presentation, please visit the "Events & Presentations" page of Revolution Medicines’ website at View Source Additionally, a replay of the webcast will be available on the "Events & Presentations" page of the Revolution Medicines website for at least 14 days following the conference.

On January 4, 2022 Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a broad portfolio of assets with different modes of action to provide a cure for people with chronic hepatitis B virus infection and to treat coronaviruses (including COVID-19), reported that the Company will participate in a virtual fireside chat at the H.C. Wainwright Bioconnect Virtual Conference taking place January 10 – 13, 2022 (Press release, Arbutus Biopharma, JAN 4, 2022, View Source [SID1234598020]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Arbutus Fireside Chat Presenters:

William Collier, President and CEO; Dr. Michael Sofia, Chief Scientific Officer; Dr. Gaston Picchio, Chief Development Officer; and David Hastings, Chief Financial Officer.

A webcast of the virtual fireside chat will be available starting at 7:00 am (EST) on Monday, January 10, 2022, and can be accessed through the Investors section of Arbutus’ website at www.arbutusbio.com. An archived replay of the webcast will be available on the Company’s website after the conference.

On January 4, 2022 Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, reported that it will participate in the following conferences in January 2022 (Press release, Vivoryon Therapeutics, JAN 4, 2022, View Source [SID1234598012]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright Bioconnect Conference

Date: January 10 − 13, 2022

Venue: virtual

Presenter: Dr. Ulrich Dauer, CEO of Vivoryon Therapeutics

A webcast of the presentation will be available from Monday, January 10, 2022, at 7:00 am ET (1:00 pm CET) via the "Presentations & Webcasts" page in the Investor Relations section on the Company’s website at www.vivoryon.com and will be archived on the Company’s website for 30 days following the conference.

J.P. Morgan Health Care Conference

Date: January 10 − 13, 2022

Venue: virtual

Participants: Dr. Ulrich Dauer, CEO, and Dr. Michael Schaeffer, CBO of Vivoryon Therapeutics

On January 4, 2022 Alamar Biosciences (Alamar), a platform company focused on transforming the field of proteomics to enable the early detection of cancer and other diseases, and Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life sciences research tools, reported a strategic partnership to further understanding of the human proteome (Press release, Abcam, JAN 4, 2022, View Source [SID1234598011]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The field of proteomic analysis is in the spotlight. Its advance not only enhances the understanding of fundamental biology, but also sheds light on the status of human health and disease. A deeper understanding of the proteome is set to play a crucial role in enabling the next wave of innovations in research, diagnostics and therapeutics. Powering this effort requires new technology platforms that are able to address the two essential goals in proteomic analysis, namely the ability to go as deeply as possible to detect very low abundance proteins and the ability to profile thousands of proteins in a single sample.

"Alamar is working to enable the early detection of cancer and other diseases by simultaneous measurement of hundreds to thousands of targets, even those present in minute amounts. We are very happy to partner with Abcam to access their extensive portfolio of recombinant monoclonal antibody pairs, which will accelerate our ability to bring our proteomic discovery tools to researchers"
Dr. Yuling Luo
Founder & CEO of Alamar

"We are excited to be partnering with Alamar as they develop an automated proteomics platform that has the potential to offer unprecedented combination of sensitivity, plex-level and dynamic range. The NULISA technology platform will provide an important tool for life science research, pharmaceutical development and diagnostics, enhancing understanding of the circulating proteome and supporting low abundance biomarker discovery. Such capability will be critical for the discovery and measurement of many proteins in human plasma and other samples that are currently undetectable."
Dr Emma Sceats
SVP Sales, Service and Business Development at Abcam

Abcam’s portfolio of over 1,300 fit-for-purpose recombinant antibody pairs is actively curated to ensure that it is representative of the key disease areas of interest. Designed to enhance biomarker discovery and support deeper understanding of the circulating proteome, the portfolio has been pre-validated specifically for multiplex applications.

On January 3, 2022 Panolos Bioscience reported on the 27th that it has signed a joint research and development contract with AimedBio, a brain disease treatment development company, for brain tumor new drug ”PB101” (Press release, Panolos Bioscience, JAN 3, 2022, View Source [SID1234633688]). Panolos is a new drug development biotech based on a multifunctional recombinant protein platform.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

PB101 is currently in the preclinical toxicity test phase, and is aiming to apply for a phase 1 clinical trial protocol (IND) next year. In addition, Panolos has signed a consignment development (CDO) contract with Samsung Biologics for PB101.

Aimed Bio plans to cooperate with Panolos by participating in the establishment of strategies for preclinical and clinical development of PB101.

Specifically, in this joint study, AimedBio selected indications for clinical development of PB101 through big data-based biomarker selection and PDC/PDX (patient derived cell/patient derived xenograft) experiments, as well as clinical trials such as non-clinical research and development of combined administration. We plan to collaborate to increase the test success rate.

PB101 is VEGF-Grab, a fusion protein in which IgG1 Fc is coupled with glycosylated VEGF1 receptor (VEGFR1). According to Panolos, PB101 can suppress all angiogenic factors such as VEGF-A, VEGF-B, and placental growth factor (PlGF) that are overexpressed in the tumor microenvironment.

Avastin, a VEGF drug currently on the market, inhibits VEGF-A, while Eylia mainly inhibits VEGF-A/B with VEGF-Trap. In addition, PIGF expression increases with the administration of existing VEGF drugs, and PIGF overexpression is associated with poor prognosis of patients, so higher anticancer efficacy is expected as PIGF is inhibited.

In addition, as a result of recent preclinical studies, it was confirmed that Panolos is superior to existing VEGF drugs in terms of cancer cell growth inhibition, blood vessel normalization, and tumor microenvironment control. The company expects additional efficacy when administered in combination with immune checkpoint inhibitors.

Nam Do-hyun, CEO of AimdBio, said, "Intractable solid cancers, including brain tumors, do not have treatments and have high unmet needs. Selecting the correct indication and establishing a clinical development strategy accordingly determines the success of new drug development." Through collaboration with transplant models and clinical experts, we want to make PB101 a success story for the solid cancer market where there is no current treatment."

Meanwhile, Panolos is building a follow-up bi-antibody/multi-antibody project that attaches additional tumor targeting and immune activating factors based on PB101 ”αARTTM”, which inhibits multiple angiogenesis factor targets.